Precision radiation oncology: A chimera that we seek
نویسندگان
چکیده
منابع مشابه
Precision Oncology: Are We There Yet?
It has been nearly four decades since Stanley Cohen was awarded the 1986 Nobel Prize in Medicine for the discovery of epidermal growth factor and its receptor EGFR. The first EGFR inhibitor, gefitinib, was approved in 2003 by theUS FDA for the treatment of advanced ormetastatic non-small cell lung cancer (NSCLC) patients as a third-line therapy, after failure of platinum-based and docetaxel che...
متن کاملAn Emerging Role for Radiation Oncology in Precision Oncology
Article history: Received 1 March 2016 Accepted 1 March 2016 Available online 4 March 2016 the precision of radiotherapy delivery (e.g. computational algorithms, IMRT, IGRT, SBRT); and3. Incorporationof novel radiosensitizing andmolecular targeting agents with radiation therapy to reduce mechanisms of radiation resistance (e.g. epithelial growth factor receptor inhibitors and RT in head and nec...
متن کاملThe fibrocyte in pulmonary hypertension: we seek him here, we seek him there.
T he fibrocyte is one of many populations of bone marrowderived cells that can be detected in the peripheral blood and is considered to represent a mesenchymal progenitor cell [1]. The fibrocyte, as we currently understand this term, was originally described by BUCALA et al. [2] in 1994 and is defined by the expression of a variety of cell surface antigens, including the stem cell marker CD34, ...
متن کاملPrecision oncology: an overview.
In this Special Series issue, Journal of Clinical Oncology presents a systematic assessment of cancer genomic information and its accelerating clinical impact. In the scientific literature and lay press, the relevant discipline is often called personalized, or precision, cancer medicine. The word personalized conveys the sense that cancer genomic data may facilitate rational treatment choices t...
متن کاملActionability and precision oncology.
Cancer is driven by molecular aberrations that allow oncogenic cells to thrive by growing and eventually metastasizing, and/or by alterations in the tumor or host that are permissive for immune evasion. The development and availability of clinical-grade molecular diagnostic tests that interrogate the genomic portfolio of each patient's tumor, together with the clinical development of a myriad o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Radiation and Cancer Research
سال: 2020
ISSN: 2588-9273
DOI: 10.4103/jrcr.jrcr_29_20